

Richter and Hetero Announce Global Cooperation for the Development and Commercialization of Semaglutide Injection (Generic of Ozempic®)

Budapest, Hungary and Hyderabad, India; 10 June 2026 – Gedeon Richter Plc. (“Richter”) and Hetero Labs Ltd. (“Hetero”) today announce the signing of a global collaboration agreement for the joint development, registration, and commercialization of Semaglutide Injection (generic of Ozempic®), strengthening their long-term partnership and expanding access to affordable treatments for patients worldwide.

The agreement combines the companies’ complementary strengths under a coordinated global framework, with clearly defined territorial responsibilities and a balanced cost- and profit-sharing model. Operating through a joint governance structure, the partners ensure aligned decision-making and efficient execution.

Hetero has already made significant development investments, including technology setup and registration batch manufacturing. Regulatory filings are underway, with EU and US submissions planned for 2027. The collaboration leverages Hetero’s proven market reach within the United States and Emerging Markets, as well as Richter’s well-established commercial infrastructure across Europe and Central Asia, while maintaining optionality for future European manufacturing by Richter.

“This collaboration reflects the strong alignment, commitment, and shared pursuit of excellence between Hetero and Richter, forming a powerful partnership. It will enable us to deliver high-quality, affordable therapies to patients living with diabetes and related cardiometabolic conditions worldwide.” said Dr. Bence Kovács, Global Head of General Medicines at Richter.

“We are delighted to collaborate with Richter, as our strategic partner for Semaglutide Injection. This strategic Partnership brings together the deep local expertise of Hetero and Richter to broaden the global access to Semaglutide Injection therapy” said Dr. Vamsi Krishna Bandi, Managing Director, Hetero Labs Ltd.

About Richter

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.8bn and sales of EUR 2.3bn in 2025, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at www.gedeonrichter.com

About Hetero

Hetero is leading global pharmaceutical company focussed on development, manufacturing and commercialization of Active Pharmaceutical Ingredients (APIs) and generic formulations. The company is dedicated to improving patient outcomes by transforming science and technology into high-quality, affordable therapies. A trusted partner to multinational pharmaceutical companies and global procurement agencies, Hetero is headquartered in

Hyderabad, India, and has a presence in over 145 countries. With more than three decades of experience, Hetero is supported by a workforce of over 30,000 professionals committed to expanding access to essential medicines worldwide. www.hetero.com

Ozempic[®], is a registered trademark of Novo Nordisk A/S.

For further information:

Richter

Investors:	Róbert Réthy, CFA	+36 20 342 2555
Media:	Zsuzsa Beke	+36 20 916 4507

Hetero

Media:	Pavan Kumar	+91 8977711038
Email:	Corp.Comm@hetero.com	